Treating inflammation is the next big breakthrough in fighting vascular disease.

Our therapeutic antibody PC-mAb is a first-in-class candidate.

Vascular inflammation in immunovascular diseases is significant but is not specifically addressed by current therapies. Athera is developing one…

learn more

Athera Biotechnologies AB is a dynamic company with a vision to address the need for improved treatment of vascular disease patients. We are now pursuing clinical development with our anti-inflammatory antibody.

our latest news